Greg Sacks is an Oncology physician affiliated with NYU Langone Health. OpenAlex indexes 139 publications with 2,042 citations (h-index 23); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
530 1st Ave
New York, NY 100166402
Telephone
212-263-7302Provider last certified this registry record 10 Jan 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year20252 payments
- Ethicon US, LLCProgram year20251 payment
- HistoSonics, IncProgram year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
60%Opioid Agonist60%Oxycodone Hcl100%Part D≥17 patientsRespiratory
40%Opioid Agonist40%Hydrocodone-Acetaminophen100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Optimizing surgical decision-making for premalignant pancreatic cysts
New York University School of Medicine
FY2026$217,288K08CA293277 - Optimizing surgical decision-making for premalignant pancreatic cysts
New York University School of Medicine
FY2025$299,168K08CA293277
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Risk of pancreatic cancer and high-grade dysplasia in resected main-duct and mixed-type intraductal papillary mucinous neoplasms: A prevalence meta-analysis
European Journal of Surgical Oncology
2025 - Outcomes in intraductal papillary mucinous neoplasm‐derived pancreatic cancer differ from PanIN‐derived pancreatic cancer
Journal of Gastroenterology and Hepatology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Harvey Pass, MD
NYU Langone Health
Gareth Morgan, MD
NYU Langone Health
Douglas Kondziolka, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”